Mode of Action
OncoQR ML´s cancer vaccines are based on the unique, proprietary, two-module S-TIR™ platform. The S-TIR™ technology was originally developed by S-TARget therapeutics for the treatment of severe allergic diseases. The vaccines are composed of a proprietary generic module (“warhead”) and a proprietary, disease-specific module (“immunogen”), linked by high-affinity connectors. In short, the warhead ensures specific delivery of the immunogen in a non-toxic manner to those cells that adjust and (re-)direct the patient’s immune response (i.e. dendritic cells and B-cells). In addition, the warhead strongly boosts and defines the therapeutic effect of the drug. The modular concept allows the combination of the warhead with different immunogens, resulting in multi-purpose cancer immunotherapies.